Dundee biotech PhaSER wins $2.7M Gates grant for infectious disease drugs
PhaSER Biomedical has a two-year, $2.7m Gates Foundation grant to give global health researchers access to its humanised 8HUM mouse model.
PhaSER Biomedical has a two-year, $2.7m Gates Foundation grant to give global health researchers access to its humanised 8HUM mouse model.
The biotech company now expects 2026 revenue growth of 15% to 25%, up from its previous guidance of up to 10%.
Emma Walmsley, the former head of biotech company GSK and a member of Microsoft’s board, will take over as HP CEO on January 4th, 2027. Bruce Broussard, who became HP’s interim CEO following Enrique Lores’ departure, will serve as chair of the board. [Link: HP Appoints Emma Walmsley as CEO, Concluding Executive Search | https://www.bloomberg.com/news/articles/2026-11-04/hp-names-emma-walmsley-as-new-ceo-ending-monthlong-search | Bloomberg]
Cambridge biotech bit.bio has raised $25m from M&G and Abcam founder Jonathan Milner to bring more lab-grown human cell types to market.
Democrat Amy Acton beat biotech entrepreneur Vivek Ramaswamy, a Republican backed by President Trump, in a race marked in the final weeks by a Ramaswamy attack ad that drew national criticism.
Genmab’s shares have doubled in three months after a string of cancer drug trial wins, strengthening its push to own more of the medicines it develops.
A biotech startup let an agent choose a gene therapy and successfully inject the treatment, offering a startling glimpse of the future of research labs.
Glytherix hopes to find a cure for challenging cancers like pancreatic, bladder, oesophageal, and glioblastoma.
The Greens want greater the government to further relax its R&D tax concessions limits which critics say are a threat to innovation.
‘We’ve also begun drug discovery efforts of our own,’ Anthropic says, as it buys Mithril and reports Claude results from six partners.
Biotech stocks are rallying as clinical wins, M&A and new drug technologies revive the sector. Here are the ETFs and stocks analysts favor.
You Can See Everything, a documentary about the disgraced biotech company founder Elizabeth Holmes, has enjoyed a record-breaking opening in the US. It is a testament to how fascinated we remain by the convicted fraudster, but what is behind the enduring appeal? US technology editor Blake Montgomery tells Madeleine Finlay why Holmes continues to fascinate us, and reflects on whether the Theranos scandal has had a permanent impact on Silicon Valley
OpenAI says it's adding Orchestra's team and technology to work on Rosalind, its AI model for life sciences research, and to its related Rosalind Workbench tool, a harness that aims to help researchers plan experiments and analyze results.
Read the latest news about biotech and health, from the most recent health tech and medical devices to research in synthetic biology and genetics.